Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
Charles D. Blanke, Cathryn Rankin, George D. Demetri, et al.·2008·Journal of Clinical Oncology